A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

OBJECTIVE: To develop gene expression profiles that characterise KRAS-, BRAF- or PIK3CA-activated- tumours, and to explore whether these profiles might be helpful in predicting the response to the epidermal growth factor receptor (EGFR) pathway inhibitors better than mutation status alone. DESIGN: F...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Sun, Simon, Iris, Moreno, Victor, Roepman, Paul, Tabernero, Josep, Snel, Mireille, van't Veer, Laura, Salazar, Ramon, Bernards, Rene, Capella, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2013
Materias:
Colon
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596735/
https://www.ncbi.nlm.nih.gov/pubmed/22798500
http://dx.doi.org/10.1136/gutjnl-2012-302423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596735/
https://www.ncbi.nlm.nih.gov/pubmed/22798500
http://dx.doi.org/10.1136/gutjnl-2012-302423

Ejemplares similares